Conduit Pharmaceuticals Inc. has entered into a joint development agreement with Manoira to advance the development of AZD1656 and AZD5658 in the animal health sector. This collaboration aims to leverage Manoira's expertise in reformulation to generate cross-species insights, accelerating the progression of human clinical programs and tapping into the estimated $15 billion animal health market. The agreement emphasizes a cost-efficient approach that enhances Conduit's pipeline while maintaining full ownership of intellectual property. This partnership underscores Conduit's strategy of innovative collaborations, seeking to redefine treatment standards in both veterinary and human applications. Under the terms, Conduit will issue Manoira $500,000 in common stock, while Manoira will fund all development activities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。